Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year

This article was originally published in The Pink Sheet Daily

Executive Summary

CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.

You may also be interested in...



Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims

FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.

Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims

FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.

Exforge Money-back Guarantee Leaves DDMAC Complaining

Novartis sales aid touting money-back guarantee on its blood pressure product implies the drug is more effective than competitors with no head-to-head evidence, FDA maintains.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel